WuXi AppTec (603259) Earnings Report: FY Revenue Hits 40.34B Yuan with a Net Income of 9.61 Billion Yuan

WuXi AppTec on Smartkarma

WuXi AppTec (2359.HK/603259.CH) has been receiving attention from top independent analysts on Smartkarma, an investment research network. Analyst Xinyao (Criss) Wang has a bearish outlook on the company due to potential bills targeting China’s CXO. The recent movement of a Senate committee bill (S.3558) could potentially affect WuXi AppTec and its subsidiaries. However, Wang suggests that these proposals are mostly “noise” and should not cause investors to be overly pessimistic. She advises the company to have “bottom-line thinking” and prepare backup solutions in case of any negative developments.

Another analyst, Brian Freitas, points out that the CSI Medical Service Index will be undergoing changes in December, with WuXi AppTec AH being a potential mover. This could result in chunky flows for some stocks, with a one-way turnover of 5.9% and a one-way trade of CNY 1.86bn (US$261m). Freitas also highlights that there may be overlap between global and local passive flows for some stocks, potentially affecting WuXi AppTec’s performance. However, he does not mention any specific sentiment towards the company, leaving it up to investors to make their own conclusions.

A look at WuXi AppTec Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

WuXi AppTec Co., Ltd. is a company that makes medical products. They make things like biological agents, antibodies, and diagnostic reagents. They also offer services like biological analysis and technical study. According to the Smartkarma Smart Scores, the company has a score of 2 for value, 4 for dividend, 5 for growth, 4 for resilience, and 2 for momentum. This indicates that the company has a positive long-term outlook, with high scores in growth and resilience. This means that the company is likely to continue growing and be able to withstand any challenges that may come its way.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma